Table 3

Multivariable analysis including ∆ NT-proBNP at 12 months and a range of variables and baseline patient characteristics known to affect prognosis

HR95% CIP value
∆ NT-proBNP at 12 months*1.071.02 to 1.130.007
Diagnostic NT-proBNP (ng/L)*1.071.02 to 1.130.006
Diagnostic troponin T (ng/L)1.011.00 to 1.020.147
Diagnostic eGFR (mL/min/1.73 m2)1.010.99 to 1.030.377
Age at diagnosis1.081.02 to 1.130.004
NYHA class at diagnosisI1
II0.740.33 to 1.650.461
≥III0.390.14 to 1.150.089
IVSd at diagnosis0.930.81 to 1.070.321
Body mass index (kg/m2)0.950.88 to 1.030.244
6 min walk test distance at diagnosis (m)†0.910.72 to 1.160.457
Atrial fibrillation0.900.50 to 1.630.738
Hypertension1.010.54 to 1.890.986
Diabetes2.190.99 to 4.860.054
Permanent pacemaker in situ0.730.31 to 1.680.454
Aortic stenosis‡1.470.53 to 4.110.459
  • ∆ NT-proBNP was calculated at the 12-month timepoint; all other variables were assessed at diagnosis.

  • P-values reaching statistical significance (p<0.05) are highlighted in bold

  • *HR for NT-proBNP is per 500 ng/L increase.

  • †HR for 6MWT distance is per 100 m increase.

  • ‡≥Moderate aortic stenosis at diagnosis; the remainder of HRs are per unit increase.

  • eGFR, estimated glomerular filtration rate; IVSd, interventricular septal thickness at end diastole; 6MWT, 6 min walk test; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.